Novillo, A.; Gaibar, M.; Romero-Lorca, A.; Malón, D.; Antón, B.; Moreno, A.; Fernández-Santander, A.
HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment. Cancers 2023, 15, 763.
https://doi.org/10.3390/cancers15030763
AMA Style
Novillo A, Gaibar M, Romero-Lorca A, Malón D, Antón B, Moreno A, Fernández-Santander A.
HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment. Cancers. 2023; 15(3):763.
https://doi.org/10.3390/cancers15030763
Chicago/Turabian Style
Novillo, Apolonia, MarÃa Gaibar, Alicia Romero-Lorca, Diego Malón, Beatriz Antón, Amalia Moreno, and Ana Fernández-Santander.
2023. "HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment" Cancers 15, no. 3: 763.
https://doi.org/10.3390/cancers15030763
APA Style
Novillo, A., Gaibar, M., Romero-Lorca, A., Malón, D., Antón, B., Moreno, A., & Fernández-Santander, A.
(2023). HER2 and BARD1 Polymorphisms in Early HER2-Positive Breast Cancer Patients: Relationship with Response to Neoadjuvant Anti-HER2 Treatment. Cancers, 15(3), 763.
https://doi.org/10.3390/cancers15030763
